EXOMA Peptides sells compounds for research use. The scientific content published on this site follows a rigorous review process to meet standards of accuracy, transparency, and traceability.
Every blog post and compendium entry is published signed by an identifiable author, with credentials, institution, and a link to their scientific team profile. Before publishing, the content is reviewed by at least one other member of the scientific team with expertise in the relevant area.
Every clinical or pharmacological claim must be backed by at least one primary source from the following categories:
Blogs, forums, social media, or third-party commercial content are never cited as a sole source.
Published Certificates of Analysis (COA) are generated from HPLC testing and other analytical techniques applied to each batch by an independent laboratory. Results visible on the site correspond to batches in circulation and are documented with batch number, date, and methodology.
Every entry carries a publication date and, when applicable, a last-reviewed date. The team revisits compendium articles when relevant new evidence appears. If content becomes outdated or inaccurate, it is corrected or withdrawn; a substantive change is never rewritten silently.
EXOMA Peptides sells compounds exclusively for research use. The site's content describes mechanisms, pharmacology, and published results; it does not constitute medical advice and does not replace consultation with a health professional.
When an author has a financial or academic relationship with a product or topic, it is explicitly declared in the entry. The editorial team maintains independence from the catalog's commercial decisions.
If a factual error is identified, it is corrected within 48 business hours. Readers can report corrections by writing to [email protected] with the reference and the proposed correction.
